Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Trial Profile

Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Durvalumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Vinorelbine
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Acronyms DURATION
  • Most Recent Events

    • 08 Jan 2018 Status changed from not yet recruiting to recruiting.
    • 31 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top